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Introduction. Orally administered preparations from the Trametes versicolor (Tv) mushroom have been hypothesized to improve
immune response in women with breast cancer after standard chemotherapy and radiotherapy. Methods.Ap h a s eI ,t w o - c e n t e r ,
dose escalation study was done to determine the maximum tolerated dose of a Tv preparation when taken daily in divided doses
for 6 weeks after recent completion of radiotherapy. Eleven participants were recruited and nine women completed the study.
Each cohort was comprised of three participants given one of three doses of Tv (3, 6, or 9grams). Immune data was collected pre-
and postradiation, at 3 on-treatment time points and after a 3-week washout. Results. Nine adverse events were reported (7 mild, 1
moderate,and 1severe), suggestingthat Tv was welltolerated.Immunologicalresultsindicatedtrendsin(1)increasedlymphocyte
counts at 6 and 9grams/day; (2) increased natural killer cell functional activity at 6grams/day; (3) dose-related increases in CD8+
Tc e l l sa n dC D 1 9 + Bc e l l s,b u tn o tC D 4 + Tc e l l so rC D 1 6 +56+ NK cells. Conclusion. These ﬁndings show that up to 9grams/day of
a Tv preparation is safe and tolerable in women with breast cancer in the postprimary treatment setting. This Tv preparation may
improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment.
1.Introduction
Trametes versicolor (Tv), also known as Coriolus versicolor
and commonly called Turkey Tail, is a mushroom species
f r o mw h i c hp r e p a r a t i o n sh a v eb e e nm a d et h a th a v ea
long history of use in traditional Asian medicine [1, 2].
Two proteoglycan fractions, polysaccharide-K (PSK) and
Polysaccharide-peptide (PSP), are similar hot water extracts
of Tv with reported anticancer activity [3, 4]. In Japan,
PSK is prescribed to cancer patients routinely, both during
and after radiation and chemotherapy [5–8]. It is also
a common practice among many naturopathic physicians
(NDs) and integrative oncologists (MDs) in the US to
prescribe whole, freeze-dried Tv to breast cancer patients
[9]. Tv immunologic activity is hypothesized to be the
main underlying mechanism responsible for its antitumor
eﬀects as well as its impact on survival rates [3, 4]. Trametes
versicolor’s mechanism of action involves enhancement of
both innate and adaptive immune responses at least in
part via Toll-like 2 receptor agonist activity [10]. Preclinical
animal studies and preliminary clinical data support the
hypothesis that Tv derivatives may be beneﬁcial in treatment
of both estrogen receptor negative and positive cancers
by mitigating immunologic depressive eﬀects of treatment
and enhancing disease-free survival via enhancement of
immunological surveillance and overcoming tumor antigen
tolerance [5, 6].
Understanding how immunologic factors are inﬂuenced
by treatments in breast cancer suggests promising areas
of focus in developing adjunctive therapies to strengthen
antitumor immune responses. Recent data demonstrate that
certain classes of chemotherapeutic drugs cause immuno-
genic tumor cell death, which lead to enhancement of
antigen cross-presentation and stimulation of the antitumor2 ISRN Oncology
immune response. Evidence suggests that NK cells play an
important role in prevention of both early and metastatic
breast cancer [11]. Some breast cancer patients have been
reported to lack NK cell activity against K562 target cells
[12]. Current data suggest that breast cancer patients who
have completed surgery, chemotherapy, and radiotherapy
have immunologic deﬁcit [13, 14]. Andersen et al. have
reported that stress levels in breast cancer patients signif-
i c a n t l yp r e d i c t e dl o w e rN Kc e l ll y s i sa sw e l la sd e c r e a s e d
proliferative response to peripheral blood lymphocytes [15].
Our previous observation study done conﬁrmed that lym-
phopenia and low NK cell activity were present throughout
the 6 weeks after the completion of radiation therapy [16].
To better understand the potential beneﬁt of Trametes
versicolor in women with breast cancer, a dose escalation
study to evaluate safety and tolerability was needed. Toward
this end, a multidisciplinary team from the University
of Minnesota and Bastyr University completed a phase 1
dose escalation trial to determine the safety and maximum
tolerated dose of Tv in women diagnosed with breast cancer
who underwent standard treatment for breast cancer and
were willing to participate in a nine-week study following
radiation therapy.
2. Methods
2.1. Study Dose Escalation. A standard phase 1 design was
usedwith3subjectsperdoseleveluntiltheMTD(maximum
tolerated dose) is reached. Dose escalation schedule for
each cohort of Tv was a 3gm (the most commonly used
dose);6gm;9gm;12gm;18gm;24gm.Thisstudyrecruited
through the nine grams cohort only (N = 9).
2.2. Study Participants. Women between the ages of 21 and
75 years, diagnosed with Stage I, II, or III breast cancer
and who had undergone surgery and chemotherapy and
were ready to start radiation therapy, were enrolled into
the study after providing written consent. Eligibility also
included willingness to eat a consistent diet throughout the
study, and avoid dietary sources of mushrooms and other
herbal products with reported immuno modulating eﬀects
during radiation therapy and until the completion of the
study. Baseline hematological, renal, and hepatic functions
within normal limits were required prior to enrolling in
the study. The study was conducted at the Cancer Center
at the University of Minnesota in Minneapolis, Minnesota
and Bastyr University in Ken more, Washington. The study
was approved by the IRB committees at the University of
Minnesota and Bastyr University. Between January 2008 and
June 2010 eleven women with stage I–III breast cancer met
the narrow criteria for this trial, consented to participate,
and were enrolled sequentially from the lowest dosage
cohort. Three participants in each of the 3gm, 6gm, and
9gm cohorts completed the study. Two of the participants
withdrew from the study after visit two because of diﬃculty
with transportation to the clinic. Characteristics of the nine
womenwhocompletedthestudyincludedanagerangefrom
38 to 68 years old; six ER negative and three ER positive;
three stage I; two stage II and four stage III breast cancers.
Oneofthewomenwhocompletedthestudydidnotundergo
chemotherapy prior to radiation, and an eligibility protocol
violation was reported to the IRB.
2.3. Outcome Measures. The primary objective of the study
was to evaluate the safety and tolerability of Trametes versi-
color in women with breast cancer in the postradiotherapy
setting. The nine participants in the dose escalation study
were monitored for adverse events (AEs) using both clinical
and laboratory methods and dose limiting toxicity (DLT)
criteria deﬁned as any Grade 2 or greater treatment-related
toxicity as scored using the NCI’s Common Terminology
Criteria for Adverse Events V 3.0 (CTCAE). Women were
screened weekly for adverse events during product admin-
istration either at their clinic visit or by telephone screening
between visits. The secondary aim was to gather preliminary
datathatcomparedpre-andpostradiation therapybaselines,
on-treatment and posttreatment immunologic measures
including complete blood count with diﬀerential, natural
killer (NK) cell activity, T regulatory cell assay, T/B/NK cell
subset assay, phagocytic index, and cytokine levels. Statistical
analysis, including independent sample t-tests and one-way
ANOVAs with Turkey post hoc multiple comparison, were
performed using GraphPad Prism, Version 5.04 (GraphPad
Software, Inc., La Jolla, CA). In order to increase power and
sample size, data from an observational study (N = 14)
conducted by our centers since 2006 [16] was combined with
the current dose escalation study (N = 9). Eligibility criteria
were identical for both studies (N = 23).
2.4. Mushroom Drug Product. Trametes versicolor freeze-
dried mycelial powder was obtained from Paul Stamets at
Fungi Perfecti, Inc., Olympia, WA and was encapsulated by
Beehive Botanicals (Hayward, WI). Each capsule contained
500mg of product. FDA IND approval (# 75,405) was
obtained in 2007.
2.5. Immune Seizures
2.5.1. Complete Blood Count with Diﬀerential. The clinical
laboratory tests (CBC, chemistry, serum pregnancy tests and
urinalysis) were performed at the Department of Labora-
tory Medicine at University of Washington for participants
recruited at the Bastyr University site and at the University of
Minnesota Fairview Diagnostic Laboratory for participants
recruited at the U of Minnesota site.
2.5.2. Natural Killer Cell Functional Activity. The immune
cells subset measured included NK cell activity, T regulatory
cell assay, T/B/NK cell subset assay, phagocytic index, and
cytokine levels. Immunological assays were conducted at
Bastyr University laboratory for subjects recruited from both
sites. Blood collected at the University of Minnesota General
Clinical Research Center (GCRC) was shipped overnight to
Bastyr University. The quality of transported blood from
University of Minnesota to Bastyr was assessed by the
following criteria. For specimens older than 48 hours whenISRN Oncology 3
they arrived at the Bastyr laboratory, the lymphocytes were
isolated, and cell viability was determined by trypan blue
staining. If the viability was greater than 80%, the assay
was performed. If the viability was less than 80%, the
specimens were rejected. Peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll-Hypaque gradient (density
= 1.070g/mL), washed twice in PBS, and maintained in
RPMI 1640, 10% FBS with 2mM L-Gln and penicillin-
streptomycin (1000U/mL; 1mg/mL). NK cell activity of
these PBMC samples, as measured by the ability to kill K562
tumor target cells, was assessed in triplicate at the eﬀector
to target (E:T) ratios of 50:1, 25:1, and 12.5:1 following
published methods [17] .T a r g e tc e l l sw e r el a b e l e dw i t h3 , 3  -
dioctadecyloxacarbocyanine perchlorate (DiOC18) and co-
cultured with PBMC eﬀector cells for four hours. A control
sample with K562 cells only was included to determine
spontaneous target cell death. Following incubation, propid-
ium iodide was added to detect dead cells. The percentage
of killed target cells was determined by subtracting the
percentage spontaneous lyses from the percent speciﬁc lysis
(PSL) of respective E:T ratio. To represent standardized NK
cell activity, lytic units were calculated by a previously pub-
lished and validated software program using the following
parameters: target per well = 10,000; LU per no. cell = 107;
curve maximum = 48; percent lyses = 20 [17]. LU20 values,
deﬁned as the E:T ratio at which 20% of target cell death
occurs, were extrapolated from dose-response curves of PSL
versus log E:T ratio for each blood sample assayed [18].
2.5.3. Immunophenotyping PBMC Subsets. PBMC suspen-
sions (5 × 105 cells) were put into 3 tubes, washed in
PBS, spun down, supernatants as pirated and cell pellets
resuspended in 100µL PBS. PBMCs in tube 1 were stained
by CD3-PC5, CD4-PE, and CD8-FITC; tube 2: CD3-PC5,
CD16-FITC, and CD56-PE; tube 3: CD14-PC5. Tubes were
vortexedbrieﬂy,coveredandincubatedonicefor15minutes,
after which cells were washed in cold PBS twice, resuspended
to 0.5mL in PBS and percent PBMC subsets determined by
ﬂowcytometricanalysisusingaBeckmanCoulterFC500and
CXP software.
2.6. Clinical Trial Protocol. The study duration was nine
weeks and started after completion of radiation therapy.
It included six weeks of product use followed by a three-
week wash outperiod of no product use (Figure 1). Patients
were screened and determined eligible for the study after
completion of chemotherapy and prior to the initiation
of radiation therapy. The study required six visits to the
clinical research centers. The ﬁrst study visit occurred prior
to the initiation of radiation therapy, at which baseline labs
were drawn. Within the ﬁrst week following completion of
radiation, participants had their second visit at which time
labs were drawn, and the nine-week study was initiated. Six
weeks of Tv product were provided for the participant, who
returned to the research center for visit three, four, and ﬁve,
two weeks apart for lab draw and assessment of product
tolerability and adverse events. The ﬁnal (sixth) visit was at
nine weeks, following three weeks oﬀ product, for a ﬁnal lab
draw and assessment for any prolonged adverse events.
The dose escalation protocol involved cohorts of a
minimum of three participants orally ingesting Tv in divided
doses daily for six weeks. The ﬁrst dose cohort took 3
grams/day in two divided doses; the second cohort took 6
grams/day in two divided doses; the third cohort took 9
grams/day in three divided doses. Three grams per day is the
most commonly used dose in naturopathic medical practice
and as high as 9 grams is used in Japan. The study goal
was to determine the maximum tolerated dose (MTD) that
demonstrated safety and tolerability (Table 1).
3. Results
3.1. Adverse Events. Findings from this dose escalation study
showed that up to 9 grams/day of Tv preparation was well
tolerated in women with breast cancer for six weeks in the
postradiation treatment setting. There were nine adverse
events; seven mild, one moderate, and only one grade 3
adverseeventswhichwasananxietyattackinoneparticipant
thatwaslikelyunrelatedtostudymedication(Table 2).Other
reported mild adverse events included transient heart burn,
heart palpitation, constipation, chest pain, fever, radiation
dermatitis, and cold/ﬂu symptoms. All three doses were well
tolerated, and participants did not experience diﬃculty in
swallowing up to 9 capsules three times daily. Of note is that
neither nausea nor GI upset was reported; two side eﬀects
were reported in previous clinical trials of other Tv extracts.
3.2. Immune Response. The red blood cell compartment
was unaﬀected by both Radiation Therapy (RT) and Tv
administration. Absolute red blood cell count, hemoglobin,
and hematocrit were normal at visit one, which was the
day before RT began, and continued to fall within normal
limits throughout the rest of the study. Absolute white
blood cell count and neutrophil counts were generally within
normal limits for all women both before and after RT
and during the weeks after RT while they were taking Tv
(data not shown). However, absolute lymphocyte counts
revealed a diﬀerent pattern from the other CBC subsets.
As eligibility criteria were identical in studies conducted
by our centers since 2006, in order to increase power, we
combined the data from our observational study (N = 14)
that showed that RT produced immune defects in women
with stage I–III breast cancer [16]w i t ho u rc u r r e n td o s e
escalation study (N = 9). For the combined number of 23
women in both studies with stage I–III breast cancer status
after breast surgery and chemotherapy who then received
radiotherapy, lymphocytes were within normal limits before
RT but dropped to abnormally low levels after RT. The
m e a nl y m p h o c y t ec o u n tf o ra l l2 3s u b j e c t sb e f o r eR Tw a s
1.027 ± 0.298 and dropped 20% after RT to 0.681 ± 0.254,
ad i ﬀerence which was statistically signiﬁcant [t(44) = 4.236,
P<0.001]. In the dose escalation study, the two higher oral
doses (6 and 9g) of Tv resulted in an earlier recovery of
lymphocyte counts (Figure 2). The number of lymphocytes
gradually recovered for the observational group, but the4 ISRN Oncology
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Figure 1: Phase I dose escalation study protocol.
Table 1: Phase I dose escalation.
Cohort Tvg/day Dose escalation timing (using escalation decision rule in next box)
13 Starting dose (dose used in clinical practice)
26
Begin after a minimum of 3 subjects in group 1 who have completed 2 weeks of product with no
dose limiting toxicity (DLT—deﬁned as any treatment related toxicity > grade 1)
39 Begin after a minimum of 3 subjects in group 2 who have completed 2 weeks of product with no
DLT
meanlymphocytecountsremainedbelowthoseforthe6and
9gmTv cohorts at 6 weeks following RT. Due to the small
number for each dose cohort (N = 3), statistical signiﬁcance
was found only between the observational and 9g groups at
the 2-week postradiotherapy time point. Radiation therapy
statistically signiﬁcantly depressed the absolute number of
lymphocytes in women with stage I–III breast cancer who
have completed surgery and chemotherapy (see Figure 2).
Natural killer cell functional activity was dramatically
reducedfrompre-topost-RTforall23breastcancerpatients
who completed the ﬁrst two visits of either the observational
study (N = 14) or the dose escalation study (N = 9).
Figure 3showsthatmeanNKcellactivitywas19.941±18.959
before RT and decreased to 9.872 ± 13.454 after RT (N =
23). This decline was statistically signiﬁcant (t(44) = 2.077,
P = 0.043). A trend toward increased NK cell activity was
observed in the 6g Tv dose cohort.
Radiation therapy statistically signiﬁcantly depressed the
NK cell function represented by the LU, which is calculated
by 107 divided doses by the LU20.T h eL U 20 is the number
of eﬀector cells (NK) required to achieve 20% speciﬁc lyses
on the target cells (K562). Therefore, the smaller the LU20,
the more eﬀective the NK cells. The interpretation of this
result might have been diﬃcult due to diﬀerential responses
of individuals upon mushroom supplementation. The trend
of temporary increase in NK cell activity was observed in the
6g dosage group (see Figure 3).
We also measured the eﬀects of radiotherapy and Tv
administration on T, B, and NK cell populations in the
nine patients who completed the phase I dose escalation
study. From the WBC and ﬂow cytometry immunophe-
notyping data, the absolute value (mm3) was calculated.
Radiotherapy had an insigniﬁcant eﬀect on CD4+ and CD8+
Tc e l l ,C D 1 9 + B cell, and CD16+/56+ NK cell populations.
Because immunophenotyping was not performed in the
observational study, the numbers of composite (pre- and
postradiation) scores were of those who participated in the
dose escalation study (N = 9). The number of CD8+
T cells was not statistically diﬀerent before and after the
radiotherapy (Figure 4). However, increases in CD8+ Tc e l l s
and CD19+ B cells were observed in peripheral blood for Tv
supplementation groups. The CD8+ T cell counts over the
9-week dose escalation study were enhanced in the 9gm Tv
dose cohort compared to both the 3g or 6g group. One-way
ANOVA was used to analyze the overall diﬀerence between
dosage groups over the treatment period (2–4–6 weeks).
It showed the statistically signiﬁcant increase in the CD8+
cytotoxic T cells for the 9g group compared to both the 3g
and 6g group (F(2, 6) = 42.04, P = 0.0003). The diﬀerence
between 3g and 6g groups was not signiﬁcant (see Figure 4).
According to the composite scores of eight dose esca-
lation participants, radiotherapy did not signiﬁcantly alter
the B cell count (Figure 5). However Tv administration
was associated with an increase in CD19+ B cells. One-way
ANOVA was used to analyze the overall diﬀerence between
dosage groups over the treatment period (2–4–6 weeks). It
showed the statistically signiﬁcant increase in CD19+ Bc e l l s
for the 6g dose group compared to the 3g group [F(2, 6) =
6.312, P = 0.0334]. The diﬀerence between the 3g and 9g
groups and also the 6g and 9g groups was not signiﬁcant
(see Figure 5).
With respect to CD16+56+ NK cell counts, no signiﬁcant
changes due to either radiotherapy or Tv administration
were observed (Figure 6). Since NK cell activity was both
decreased by RT and increased in the 6 gram Tv dose
cohort (Figure 3), but NK cell populations appeared notISRN Oncology 5
Table 2: Adverse event reporting.
Grade Frequency Dose Description Relation Expectation
Mild 7
3g Heartburn Possibly related Unexpected
3g Heart palpitations Unlikely related Unexpected
6g Constipation Unlikely related Unexpected
6g Chest pain Possibly related Unexpected
6g Fever with concomitant R dermatitis (2) Unlikely related Unexpected
9g Cold or Flu-like symptoms Unlikely related Unexpected
Moderate 1 6g Fatigue; secondary to UT infection Unlikely related Unexpected
Severe 1 6g Anxiety event Possibly related Unexpected
Total 9
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to be signiﬁcantly inﬂuenced by these treatments, the data
suggest that enhancement of NK cell activity is not due to
treatment-inducedalterationsinthenumberofNKcells.NK
cell population was unaﬀected by either radiotherapy or by
oral doses of Tv (see Figure 6).
4. Discussion
Findings from this study establish the safety of oral adminis-
tration of a Trametes versicolor (Tv) preparation at 3, 6, and 9
gram doses, with no serious adverse events of this therapy
in women following radiation therapy for breast cancer
treatment. The current study conﬁrms our earlier report that
standard chest radiotherapy for breast cancer does not aﬀect
the red blood cell compartment or neutrophils but does
induce speciﬁc immune deﬁciencies including lymphopenia
and depressed NK cell functional activity [16, 19]. NK cell
therapies are emerging worldwide as promising anticancer
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treatments,exploitingthefastcytolyticactionofNKeﬀectors
and their potentially broad applicability against a wide range
of malignancies [20–22]. Our new ﬁnding is that the loss of
NK cell activity appears to be independent of the number
of NK cells. Here, we show that RT reduces NK cell activity
per NK cell. Higher oral doses of Tv at 6 and 9 grams/day
were associated with faster recovery of lymphocytes and
NK cell activity, as well as increased numbers of CD8+T
cells and CD19+ B cells. There was no evident eﬀect of
Tv on the number of CD 16+/56+ NK cells, only on their
functional activity. While there is a trend toward higher Tv
doses having more pronounced immunological activity, this
phase I dose escalation trial was not designed to evaluate
dose-dependent changes in immune markers. Preliminary
data with these small samples of 3 breast cancer patients per
dose cohort group showing dose-related trends lead to the
testable hypothesis that 6 grams of Tv may lead to faster
immunerecoveryafterradiotherapy.Theresultsofthisphase6 ISRN Oncology
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I trial justify and stand as the platform upon which phase II
randomized controlled dose-response trials may proceed.
Although this study showed safety of Trametes versicolor
to a 9-gram daily dose, the dose escalation study was
designed to assess the maximum dose tolerated (MDT);
therefore this study did not determine safety and tolerability
at the highest dose. Recruitment of women into a 12-gram
cohort and higher was not achieved because of multiple
limiting factors. First, women had to meet very strict
eligibility criteria to enroll in the study and be undergoing
surgery, chemotherapy, and radiation in their treatment
protocol. Currently, many women with a breast cancer
diagnosis do not receive a triple therapy regimen. Many
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womenarediagnosedwithstage1breastcancerandundergo
lumpectomy and radiation, and if their oncotype score
is low, they do not receive chemotherapy. Additionally,
many women were recruited into other research studies and
were saturated with requests to enroll in additional studies.
Most importantly, we found that women after completing a
lengthy treatment regimen of chemotherapy and radiation
were reluctant to participate in a nine-week study that
required six additional visits to the University.
The phase I data suggest that Tv is a safe immunotherapy
for breast cancer patients that may correct radiotherapy-
related immune defects. Based on our ﬁndings, Tv mush-
room therapy orally administered in the postradiotherapy
setting may enhance lymphocyte numbers and NK cell
tumoricidal activity. Relapse after primary breast cancer
treatmentmayberelatedtodefectsintheinnateandadaptive
immunesystem.Researchbyourcentercontinuestoindicate
that Trametes versicolor represents a novel immune therapy
with signiﬁcant applications in cancer treatment.
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